[Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes]

Nihon Yakurigaku Zasshi. 2015 Jan;145(1):36-42. doi: 10.1254/fpj.145.36.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Design
  • Glucosides / chemistry
  • Glucosides / pharmacology*
  • Humans
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors
  • Thiophenes / chemistry
  • Thiophenes / pharmacology*

Substances

  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Thiophenes
  • ipragliflozin